What is the primary treatment for Kawasaki disease?

The primary treatment for Kawasaki disease is aspirin and intravenous immunoglobulin (IVIG). Kawasaki disease is an acute vasculitis that primarily affects children and can lead to serious complications, like coronary artery aneurysms, if not treated promptly.

Aspirin is used due to its anti-inflammatory properties and its ability to reduce the risk of thrombosis, which is crucial in preventing coronary artery complications associated with the disease. High-dose IVIG is administered to reduce inflammation and the risk of heart-related issues, making it a cornerstone of therapy. This combination helps to quickly reduce fever and inflammation, improve the recovery process, and protect the cardiovascular system in affected children.

Other treatment options, such as glucocorticoids, may be used in certain severe cases or in specific patient populations but are not the standard first-line treatment for Kawasaki disease. Intravenous antibiotics address infections but are not relevant in this context since Kawasaki disease is not caused by an infectious agent. Beta-blockers, while important in managing certain cardiac conditions, do not address the underlying inflammatory process or the immediate complications associated with Kawasaki disease. Thus, the combined use of aspirin and IVIG is the most effective and established treatment protocol for this condition.